KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Net Cash Flow (2016 - 2025)

Vertex Pharmaceuticals has reported Net Cash Flow over the past 17 years, most recently at $132.7 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $132.7 million for Q4 2025, up 121.11% from a year ago — trailing twelve months through Dec 2025 was $424.7 million (up 107.38% YoY), and the annual figure for FY2025 was $424.7 million, up 107.38%.
  • Net Cash Flow for Q4 2025 was $132.7 million at Vertex Pharmaceuticals, up from -$30.1 million in the prior quarter.
  • Over the last five years, Net Cash Flow for VRTX hit a ceiling of $1.3 billion in Q4 2022 and a floor of -$4.6 billion in Q2 2024.
  • Median Net Cash Flow over the past 5 years was $228.5 million (2021), compared with a mean of -$46.7 million.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 558.1% in 2022 and later plummeted 639.74% in 2024.
  • Vertex Pharmaceuticals' Net Cash Flow stood at $524.8 million in 2021, then surged by 146.61% to $1.3 billion in 2022, then crashed by 159.63% to -$771.7 million in 2023, then grew by 18.54% to -$628.6 million in 2024, then skyrocketed by 121.11% to $132.7 million in 2025.
  • The last three reported values for Net Cash Flow were $132.7 million (Q4 2025), -$30.1 million (Q3 2025), and $239.4 million (Q2 2025) per Business Quant data.